Effecty and security of Gemcitabine and S-1 in the treatment of metastatic triple-negative breast cancer
10.3760/cma.j.issn.1674-6090.2015.01.013
- VernacularTitle:吉西他滨联合替吉奥胶囊三线治疗转移性三阴乳腺癌的疗效和安全性
- Author:
Shuxian QU
;
Zhendong ZHENG
;
Zhaozhe LIU
;
Liang LIU
;
Miao ZHANG
;
Yaling HAN
;
Xiaodong XIE
- Publication Type:Journal Article
- Keywords:
S-1;
Gemcitabine;
Metastatic breast cancer;
Chemotherapy
- From:
Journal of Endocrine Surgery
2015;9(1):41-44
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect and toxicity of gemcitabine and S-1 in treatment of metastatic triple-negative breast cancer.Methods In this study,41 cases of metastatic breast cancer were treated in the General Hospital of Shenyang Military Region between Jun.2010 and Dec.2012.The median age was 55 years old.The pathological diagnosis of these patients was triple-negative breast cancer.All patients were given gemcitabine 1000 mg/m2 intravenously on the 1st and 8th day,and 60 mg S-1 from the 1st day to the 14th day orally for every cycle.There were 21 days for each cycle.All patients accepted at least 2 cycles of chemotherapy and once effect evaluation.Results 41 cases were diagnosed as metastatic triple-negative breast cancer,with the failure of second-line treatment.The median age was 55 years.All cases were followed up until death.All the 41 cases were administrated for more than 2 cycles,among whom,there were 0 case of complete response(CR),16 cases (39.0％)of partial response(PR),14 cases(34.1％) of stable disease(SD),and 11 cases(26.8％) of progressive disease(PD).The disease control rate was 73.1％ (30/41).In this study,median progression free survival(mPFS)was 7.9 months.The rate of digestive toxicity and marrow suppression was 24.4％ and 55％ respectively.No patient stopped treatment because of severe toxicities.Conclusion The chemotherapy regimen of gemcitabine and S-1 is effective in treatment of metastatic triple-negative breast cancer,and the toxicity could be tolerated.
